Physician profile
Jawaad Khokhar
NPI 1336272707
$154,802.34
in general payments reported to CMS, 2019-2025
37 companies · $61K in 2025
The $61K reported for 2025 was more than what 96% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $17K · 2021: $9,758 · 2022: $21K · 2023: $1,014 · 2024: $28K · 2025: $61K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Honoraria: $33K · Food and Beverage: $6,507 · Travel and Lodging: $3,539 · Education: $46.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $47,107.50 |
| Honoraria | $32,667.50 |
| Food and Beverage | $6,507.20 |
| Travel and Lodging | $3,539.20 |
| Education | $46.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $113,034.67 | 2019-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $20,947.96 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $12,647.41 | 2019-2025 | |
| Novo Nordisk INC | $1,912.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,572.43 | 2019-2022 | |
| Lilly USA, LLC | $874.74 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Mannkind Corporation | $715.92 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $474.67 | 2019-2024 | Jardiance |
| Dexcom, INC. | $415.95 | 2019-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $312.73 | 2020-2024 | Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $213.86 | 2019 | |
| Merck Sharp & Dohme LLC | $152.81 | 2019-2021 | |
| Amgen INC. | $134.22 | 2019-2024 | Tepezza, Prolia, Evenity |
| Alexion Pharmaceuticals, INC. | $114.81 | 2019-2020 | |
| Abbvie INC. | $105.12 | 2020-2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $97.87 | 2023-2024 | Tymlos |
| Shire North American Group INC | $91.90 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $79.22 | 2019 | |
| Novartis Pharmaceuticals Corporation | $77.07 | 2023 | |
| Beta Bionics, INC. | $76.49 | 2024 | Ilet Bionic Pancreas |
| Eisai INC. | $75.37 | 2019 | |
| Tandem Diabetes Care, INC. | $71.16 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Horizon Therapeutics Plc | $62.43 | 2019-2021 | |
| Kyowa Kirin, INC. | $62.36 | 2023-2024 | Crysvita |
| Medtronic, INC. | $56.68 | 2021-2023 | Minimed 780g |
| Amneal Pharmaceuticals LLC | $54.58 | 2022-2024 | Unithroid |
| Cequr Corporation | $54.37 | 2022-2024 | Cequr Simplicity |
| Medtronic Minimed, INC. | $54.28 | 2020 | |
| Ibsa Pharma INC. | $45.17 | 2019-2021 | |
| Insulet Corporation | $42.08 | 2023-2024 | Omnipod |
| Amarin Pharma, INC. | $41.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.96 | 2024 | |
| Amphastar Pharmaceuticals, INC. | $28.14 | 2024 | |
| Lifescan, INC. | $19.51 | 2019 | |
| Clarus Therapeutics INC. | $18.09 | 2021 | |
| Companion Medical, INC. | $17.89 | 2020 | |
| Almatica Pharma LLC | $15.61 | 2024 | Teriparatide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jawaad Khokhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.